FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

$0 vol

Order book

Market Rules

Resolves Yes if the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval.Outcome verified from AppliedXL.

This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.

Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep. It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions. This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.

Note: this event is mutually exclusive.

Timeline and payout

Market openJun 17, 2026 · 5:00pm EDT

Market closesAfter the outcome occurs

Projected payout30 minutes after closing

This market will close early if the FDA issues a decision on Bepirovirsen before Jan 1, 2027 Otherwise, it closes by Dec 31, 2026 at 11:59pm EST.

SeriesKXBEPIROVIRSEN

EventKXBEPIROVIRSEN-27

MarketKXBEPIROVIRSEN-27-Y

Insider trading is prohibited

The following are prohibited from trading this contract:

Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.